Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions (Q38601723)

4 September 2017

title

Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions (English)

1 reference

4 September 2017

main subject

acute myeloid leukemia

1 reference

2

Farhad Ravandi

1 reference

4 September 2017

David Sanford

1

1 reference

4 September 2017

publication date

7 October 2015

1 reference

4 September 2017

1 reference

4 September 2017

volume

32

1 reference

4 September 2017

issue

12

1 reference

4 September 2017

page(s)

983-997

1 reference

Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005.

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

On the value of intensive remission-induction chemotherapy in elderly patients of 65 years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

High-dose daunorubicin in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Age and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Decitabine in older adults with acute myeloid leukemia: why was the dream broken?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

The mechanisms of IDH mutations in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

Characterization of acute myeloid leukemia based on levels of global hydroxymethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0309-2

21 January 2018

The geriatric assessment

1 reference

12 December 2020

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

1 reference

12 December 2020

Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia

1 reference

12 December 2020

Treatment of acute myeloid leukemia: are we making progress?

1 reference

12 December 2020

Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia

1 reference

12 December 2020

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

12 December 2020

Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration

1 reference

12 December 2020

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.

1 reference

12 December 2020

The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial

1 reference

12 December 2020

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients

1 reference

12 December 2020

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

1 reference

12 December 2020

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

1 reference

12 December 2020

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

1 reference

12 December 2020

Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system

1 reference

12 December 2020

Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).

1 reference

12 December 2020

10.1007/S40266-015-0309-2

Identifiers

DOI

1 reference

4 September 2017

1 reference